



Scientific Posters

ARV-based Prevention: Perinatally Acquired HIV

P001	Increasing numbers of pregnancies to women with vertically-acquired HIV in the UK: 2006 to 2021 <i>H Peters*</i> ; <i>K Francis</i> ; <i>L Bukasa</i> ; <i>R Sconza</i> ; <i>C Thorne (London, UK)</i>
P002	HIV vertical transmission in England: the current picture <i>K Francis*</i> ; <i>H Peters</i> ; <i>L Bukasa</i> ; <i>R Sconza</i> ; <i>C Thorne (London, UK)</i>
P003	Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study <i>K Aebi-Popp</i> ; <i>C Kahlert</i> ; <i>P Crisinel</i> ; <i>L Decosterd</i> ; <i>S Alves Saldanha</i> ; <i>I Hösli</i> ; <i>B Martinez Tejada</i> ; <i>A Duppenhaler</i> ; <i>A Rauch</i> ; <i>C Marzolini*</i> (Bern, Switzerland)
P005	Could Dolutegravir/Lamivudine be a valid dual-therapy option even in pregnancy? Data from a retrospective analysis <i>L Pagnucco*</i> ; <i>R Bruno</i> ; <i>V Zuccaro</i> ; <i>L Maiocchi</i> ; <i>S Novati</i> ; <i>M Roccio</i> ; <i>L Zanchi</i> ; <i>C Melito</i> ; <i>G Bossi</i> ; <i>A Borghesi</i> ; <i>R Gulminetti (Pavia, Italy)</i>
P006	Transplacental transfer of bictegravir versus dolutegravir in human placenta <i>A Mohammed*</i> ; <i>M Lehtonen</i> ; <i>N Tepponen</i> ; <i>M Forsberg</i> ; <i>K Vähäkangas (Kuopio, Finland)</i>

ARV-based Prevention: PEP/PrEP/TasP

P007	Pre-exposure prophylaxis (PrEP) in Poland 2017 to 2021: lessons from a country with no national PrEP programme <i>B Szetela*</i> ; <i>I Cielniak</i> ; <i>J Kubicka</i> ; <i>T Rojewski</i> ; <i>A Katafias</i> ; <i>P Jakubowski</i> ; <i>M Hlebowicz</i> ; <i>M Sitko</i> ; <i>J Loster</i> ; <i>O Jablonowska</i> ; <i>A Cybula</i> ; <i>B Aksak-Wąs</i> ; <i>K Gierlotka</i> ; <i>M Bociaga-Jasik</i> ; <i>M Parczewski</i> ; <i>R Szymanski</i> ; <i>W Bludzin</i> ; <i>A Grzeszczuk</i> ; <i>W Niemczyk</i> ; <i>K Giniewicz</i> ; <i>M Rosinska</i> ; <i>J Gasiorowski (Wroclaw, Poland)</i>
P008	Comparison of HIV incidence as determined by two different recency assays in Ugandan women <i>S Cox*</i> ; <i>E Grebe</i> ; <i>A Kintu</i> ; <i>Y Shao</i> ; <i>F Matova Kiweewa</i> ; <i>Z Lukyamuzi</i> ; <i>F Kiweewa</i> ; <i>S Facente</i> ; <i>R Ebrahimi</i> ; <i>C Carter</i> ; <i>C Callebaut</i> ; <i>J Baeten</i> ; <i>M Das (Foster City, CA, USA)</i>
P009	Prescription adherence and persistence on oral pre-exposure prophylaxis (PrEP) among prep-naive (PN) individuals after FTC/TAF approval in the United States (US) <i>R Elion</i> ; <i>J Gruber</i> ; <i>J Radtchenko*</i> ; <i>M Dunbar</i> ; <i>K Mayer</i> ; <i>G Huhn</i> ; <i>K Mounzer</i> ; <i>A Mills (Louisville, CO, USA)</i>
P010	Viral hepatitis and human papillomavirus vaccination during pre-exposure prophylaxis: factors associated with missed vaccination <i>A Raccagni*</i> ; <i>D Ceccarelli</i> ; <i>B Trentacapilli</i> ; <i>L Galli</i> ; <i>R Lolatto</i> ; <i>D Canetti</i> ; <i>E Bruzzesi</i> ; <i>C Candela</i> ; <i>A Castagna</i> ; <i>S Nozza (Milan, Italy)</i>
P011	Evaluation of doravirine/lamivudine/tenofovir disoproxil fumarate for non-occupational post-exposure prophylaxis, a prospective open-label study (DORAVIPEP) <i>A Inciarte*</i> ; <i>A Ugarte</i> ; <i>B Torres</i> ; <i>M Martinez-Rebollar</i> ; <i>M Laguno</i> ; <i>J Ambrosioni</i> ; <i>I Chivite</i> ; <i>D Agüero</i> ; <i>V Rico</i> ; <i>L Berrocal</i> ; <i>A González-Cordón</i> ; <i>P Puerta</i> ; <i>L De La Mora</i> ; <i>E De Iazarrí</i> ; <i>S Herrera</i> ; <i>N García-Pouton</i> ; <i>M Hernandez-Meneses</i> ; <i>R Alonso</i> ; <i>P Monzo</i> ; <i>P Callau</i> ; <i>R Aguiló</i> ; <i>E Fernández</i> ; <i>L Barrero</i> ; <i>E Solbes</i> ; <i>E Martínez</i> ; <i>J Blanco</i> ; <i>J Miró</i> ; <i>A Soriano</i> ; <i>J Mallolas (Barcelona, Spain)</i>
P012	Willingness to use long-acting injectable PrEP among key populations at a large HIV prevention clinic in Kampala, Uganda <i>D Lukubuya*</i> ; <i>M Baguma</i> ; <i>A Kaguta</i> ; <i>W Nambatya</i> ; <i>P Kyambadde</i> ; <i>E Katana</i> ; <i>T Muwonge</i> ; <i>E Odongpiny (Kampala, Uganda)</i>



Scientific Posters

ARV-based Prevention: PEP/PrEP/TasP (continued)

P013 Virtual	Determinants of intention to use pre-exposure prophylaxis and condom use among female sex workers in Madrid, Spain <i>L Vazquez Guillamet*</i> ; J Valencia; P Ryan; I Cobo; J Lazarus; G Chevance (Barcelona, Spain)
P014	Are PrEP and other HIV prevention methods used by people experiencing homelessness in London? <i>E Pool*</i> ; P Pierce; J Gibbons; A Story; D Menezes; J Surey; B Sultan (London, UK)
P015	Impact of the COVID-19 pandemic on sexual behaviour and welfare of HIV preexposure prophylaxis users in Northern France: a prospective quantitative and qualitative monocentric study <i>A Meybeck*</i> ; A Kamadjou; A Decock; T Huleux; A Depreux; E Aissi; L Landre; V Baclet; N Viget; M Valette; O Robineau (Tourcoing, France)
P016	HIV pre-exposure prophylaxis services, provision, and delivery in the NEAT ID network <i>G Liegeon; A Duffy; C Brooks; H Honour; J Molina*</i> ; on behalf of the PrEP NEAT ID Study Group (Paris, France)
P017 Virtual	Post-trial oral pre-exposure prophylaxis (PrEP) access among women who used oral PrEP as HIV prevention standard of care during a large clinical trial: findings from Durban, South Africa <i>I Beesham*</i> ; M Beksinska; C Milford; J Smit; L Mansoor (Durban South, Africa)
P018	Characterisation of a population on PrEP and loss to follow-up <i>R Sousa*</i> ; R Domingos; J Alves; S Peres; A Silva; T Baptista Alberto; K Mansinho (Matosinhos, Portugal)
P019	Profile and prevention trajectory of recently HIV infected patients in Belgium <i>C Vanden Bulcke*</i> ; J Deblonde; S Callens; C Verhofstede (Ghent, Belgium)
P021	High acceptance of same-night PrEP start in a safer space for trans and male sex workers: the Night Café <i>B Hampel*</i> ; L Guelfi; J Real; B Zahno; J Fehr (Zurich, Switzerland)
P022	HCV infection in an outpatient PrEP clinic in a Portuguese tertiary hospital <i>M Miguel*</i> ; J Lourinho; H Pires; T Nunes; D Lages; A Gomes; L Duque; J Botas; N Marques (Lisbon, Portugal)
P023	Post-exposure prophylaxis and pre-exposure prophylaxis in gay, bisexual, and other men who have sex with men who practise sexualised drug use <i>D Íncera; J Garrido; M Gámez; I Zaro; L García*</i> ; A García; L Ibarguchi (Madrid, Spain)
P024	Pre-exposure prophylaxis (PrEP) uptake and adherence experiences of gay and bisexual men who engage in chemsex: a qualitative study <i>S Maxwell*</i> ; M Gafos; M Shahmanesh (Glasgow, UK)

Treatment Strategies: New Treatments and Targets

P026	Week 52 subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase II/III in heavily treatment-experienced people with multidrug-resistant HIV (CAPELLA study) <i>A Castagna*</i> ; J Blanco; C Hung; M Rassool; M Ramgopal; W Sanchez; C Cretico; D Hagins; D Wheeler; H Wang; I Henne; H Dvory-Sobol; M Rhee; J Baeten; O Onyema (Milan, Italy)
P027	Common adverse events in clinical studies of people using lenacapavir for HIV treatment <i>A Antinori*</i> ; F Castelli; S Ronot-Bregigeon; Y Yazdanpanah; R Safran; D Berger; P Cook; G Sinclair; H Wang; G Saunders; T Farrow; H Dvory-Sobol; M Rhee; J Baeten; S Gupta (Rome, Italy)



Scientific Posters

Treatment Strategies: New Treatments and Targets (continued)

P028	VICDOR: Effectiveness of switching to DOR-based antiretroviral therapy (ART) under real-world conditions in Germany <i>J Rockstroh*</i> ; C Wyen; M Sabranski; H Knechten; S Esser; N Qurishi; C Jonsson-Oldenbüttel; J Bogner; S Schellberg; I Kolobova; J Pelz; Y Whiteside (Bonn, Germany)
P029	The implementation of every-2-months cabotegravir and rilpivirine long-acting injections from the perspective of healthcare providers in the German CARLOS cohort, 6-month outcomes <i>J Scherzer*</i> ; C Jonsson-Oldenbuettel; S Schneeweiß; C Wyen; J Borch; K Ummard-Berger; N Postel; E Rodriguez; C Gutner; K Dymek; B Westermayer; K Bernhardt (Munich, Germany)
P030	Fostemsavir and QT prolongation: clinical applications for co-administration with other agents <i>S Patel; V Vega; A Dyson*</i> ; R Guduru; G Morcos; M Calderón; A Mannebach; B Gilliam; A Clark; A Tenorio; K Moore (Durham, NC, USA)
P031	Patterns of doravirine use in a US cohort <i>M Sension*</i> ; L Brunet; R Hsu; K Mounzer; J Fusco; Y Whiteside; J Arduino; I Kolobova; G Fusco (Sarasota, FL, USA)
P032	Development of conceptual models to understand patient experiences with and attributes of adherence to HIV oral antiretroviral therapy and considerations in switching to long-acting oral antiretroviral therapy <i>J Bailey; P Javidnia; J Mao; A Borsa; E Hawryluk; S Gubernick; A de la Motte; E Fonseca*</i> ; S Karantzoulis; M Reaney; T Saretsky (Rahway, NJ, USA)
P033 Virtual	Pediatric dolutegravir introduction for children living with HIV (CLWHIV) in Zimbabwe: lessons from early adopter sites <i>C Giyava*</i> ; N Kawaza; C Chimhundu; A Mushavi; P Andifasi; A Mangwiro (Harare, Zimbabwe)
P034	Rescue therapy with ibalizumab in HIV multi-drug resistances (MDR) patient <i>S Martini*</i> ; N Cuomo; M Pisaturo; N Coppola (Naples, Italy)

Treatment Strategies - Target Populations: Adolescents and Children

P035	Treatment-emergent integrase inhibitor resistance among pediatric and adolescent HIV-1 populations: a systematic review <i>C Henegar; C Brothers; C Vavro; L Tan; M McKenna; V Vannappagari*</i> ; A Buchanan (Durham, NC, USA)
P036	Pediatric dolutegravir is highly preferred by patients/caregivers in Nigeria and Uganda at 1 month after initiation <i>J Campbell; B Ngwatu*</i> , and the TORPEDO study teams in Nigeria and Uganda (Kampala, Uganda)

Treatment Strategies - Target Populations: Ageing Population

P038	Switch to bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV aged 65 years or older: W24 results of the BICOLDER study - IMEA 057 <i>C Allavena*</i> ; V Joly; L Assoumou; V Isernia; F Ajana; D Neau; D Descamps; C Charpentier; A Benalycherif; E Metivier; G Peytavin; B Phung; R Landman (Paris, France)
P039 Virtual	PROximity: digitisation in the active listening of the HIV patient; mental health as a care priority <i>A Díaz de Santiago; S de la Fuente Moral; M Corrales Rodríguez; J Martín Giner; C Folguera Olías; B Menchén Viso; A Planes Roy*</i> ; R Roldán Blay (Valencia, Spain)



Scientific Posters

Treatment Strategies - Target Populations: Women

P040	Adverse birth outcomes and risk of MTCT for dolutegravir versus efavirenz in five randomised trials of 1074 pregnant women <i>S Sokhela; F Venter; B Bosch; G Akpomiemie; A Tembo; T Pepperrell; B Simmons; L Mulenga; A Calmy; T Sanchez; E Delaporte; C Casas; S Khoo; H Reynolds; A Hill* (Liverpool, UK)</i>
P041	Supported breastfeeding among women living with HIV in the UK: the current picture <i>K Francis*; C Thorne; R Sconza; H Peters (London, UK)</i>
P042	Interim doravirine safety results from a pilot switch study for women of childbearing potential in South Africa <i>J Woods; S Sokhela; B Bosch*; G Akpomiemie (Johannesburg, South Africa)</i>
P043	Guidelines and practice of breastfeeding in women living with HIV: a European survey <i>A Keane*; F Lyons; K Aebi-Popp; C Feiterna-Sperling; H Lyall; A Martínez Hoffart; H Scherpbier; C Thorne; H Albayrak Ucak; A Haberl (Dublin, Ireland)</i>
P044	Real-world experience with the two-drug regimen dolutegravir and lamivudine in women with HIV: a systematic literature review <i>S di Giambenedetto; S Walmsley; B Grinsztejn; M Pérez Elías; N Nwokolo; M Kabra; B Jones; E Letang; M Kisare* (Nairobi, Kenya)</i>
P045	A wonderful experience: a difficult decision - feedback from breastfeeding mothers living with HIV in Germany (SISTER study) <i>L Haberl*; F Audebert; F Borkel; H Dorsch; J Eger; C Feiterna-Sperling; D Gillor; U Haars; P Jakubowski; C Jonsson-Oldenbüttel; P Khaykin; R Kiener; A Reitter; A Rieke; S Rößler; I Rohr; J Rump; G Schüttfort; M Speer; C Stephan; A Ulmer; A von Braun; K von Weizsäcker; A Haberl (Düsseldorf, Germany)</i>
P046	HIV testing reasons from 2000 to 2020 in an active cohort of women living with HIV (WLWHIV) in a tertiary hospital in Barcelona, Spain: a retrospective study <i>S Toyos; L Berrocal; A González-Cordón; E Fernández; A Inciarte; L de la Mora; M Martínez-Rebollar; M Laguno; J Ambrosioni; I Chivite; E de Lazzari; J Blanco; E Martínez; J Miró; J Mallolas; B Torres* (Barcelona, Spain)</i>
P047	HIV and women in Latin America: characteristics, therapy, and outcomes - results from the Latin American HIV Workshop Study Group (LAHWSG) <i>P Zitko*; I Casetti; P Celi; E Barthel; C Mazariegos; S Pereira; M Rodriguez; L Astocondor; E Álvarez; C Beltran (Santiago, Chile)</i>
P048	Under the covers: HIV and women in Saskatchewan, Canada <i>C Spence*; D Magnusson; L Kiesman; B Wudel; E Yip-Liang; S Kogilwaimath (Saskatoon, Canada)</i>

Treatment Strategies - Target Populations: Late Presenters

P049	Effects of advanced HIV disease on inflammation following ART initiation <i>O Bisbal*; S Serrano-Villar; L Domínguez-Domínguez; M Rava; C Guitierrez; A Rull; L Pérez-LaTorre; F Gutierrez; M Saumoy; C Amador; I Jarrín; J Iribarren; R Rubio; S Moreno (Madrid, Spain)</i>
P050	Comparison of the efficacy of preferred antiretroviral regimens in patients with CD4 cell counts <200 versus 200/L or VL >100 000 versus 100 000 copies/mL: a systematic review with meta-analysis. GESIDA-11520 Study <i>J Perez-Molina; C Crespillo-Andujar; J Zamora; B Fernández-Félix; A Gaetano; J López Bernaldo de Quirós; S Serrano-Villar; S Moreno*; J Berenguer (Madrid, Spain)</i>



Scientific Posters

Treatment Strategies - Target Populations: Late Presenters (continued)

P051	Predictors of HIV late presentation and barriers to the HIV testing in Central region of Ukraine <i>T Koval*; O Marchenko; A Mischenko; S Nesterenko (Poltava, Ukraine)</i>
P052	High rates of virological suppression after 24 weeks of tenofovir alafenamide/emtricitabine/bictegravir (BIC/FTC/TAF) in people living with HIV (PLWHIV) starting antiretroviral therapy with <200 CD4 cell count <i>I Pérez Valero; D Corona Mata*; A Camacho Espejo; C Roca-Oporto; C Tomas; N Cabello; M Cervero Jimenez; M Navarro; A Rivero-Juarez; A Rivero Roman (Cordoba, Spain)</i>
P053 Virtual	Risk factors associated with late presentation to HIV care in the 'treat all' era in sub-Saharan Africa: a systematic literature review <i>D Mwamba* (Lusaka, Zambia)</i>

Treatment Strategies - Target Populations: Naive Patients

P054 Virtual	Transmitted drug resistance in Spain (CoRIS) patients during 2019 to 2021 <i>L Viñuela; A Fuentes-López; A de Salazar; E Serrano-Conde; M Pérez-Elias; J Olalla; O Arce-García; J Iribarren; M Masiá; M Montero; I Falces-Romero; J Blanco; M Rivero; L García-Fraile; N Espinosa; B Baza; A Aguilera; M Maciá; M Martínez-Velasco; A Iborra; A Imaz; A López Lirola; J Peraire; I Portilla; A Rando; I Suarez; R Izquierdo; F Garcia* (Granada, Spain)</i>
P055 Virtual	Phenotypic analysis of the impact of V106I in HIV-1 reverse transcriptase on resistance to doravirine <i>F Saladini; A de Salazar; A Fuentes; L Viñuela; F Giammarino; N Bartolini; C Charpentie; S Lambert-Niclot; G Sterrantino; G Colao; V Micheli; A Bertoli; L Fabeni; I Malet; E Teyssou; R Delgado; I Falces; A Aguilera; P Gomes; D Paraskevis; M Santoro; A Marcelin; F Ceccherini-Silberstein; M Zazzi; F Garcia* (Granada, Spain)</i>
P056	High efficacy of dolutegravir/lamivudine (DTG/3TC) in treatment-naive adults with HIV-1 and high baseline viral load (VL): 48-week subgroup analyses of the GEMINI-1/-2 and STAT trials <i>C Rolle*; J Arribas; R Ortiz; J Matthews; C Man; R Grove; C Donovan; B Wynne; M Kisare; B Jones (Nairobi, Kenya)</i>
P057	Real-world use of dolutegravir/lamivudine in treatment-naïve people living with HIV during the COVID pandemic <i>G Pierone, Jr.*; J Fusco; L Brunet; V Vannappagari; S Sarkar; C Henegar; J van Wyk; A Zolopa; G Fusco (Vero Beach, FL, USA)</i>
P058	BICNOW clinical trial: preliminary results of rapid test and treat BIC/FTC/TAF study in naive PLWHIV <i>C Hidalgo-Tenorio*; S Sequera; A Collado; M Vivancos; I De los Santos; P Sorni; N Cabello; M Montero; A Terrón; O Martinez; M Omar Mohamed; P Ryan; M Galindo; J Pasquau; R Javier; M Lopez Ruz; C Garcia Vallecillos (Granada, Spain)</i>
P059	96 weeks effectiveness and tolerability of DTG+3TC in naive patients: the REDOLA study <i>F Pulido; J López Bernaldo de Quiros; M Górgolas; M Torralba; L Martín-Carbonero; Á Mena; J Sanz; J Vergas; Á Gutiérrez*; M Hernández-Segurado; E Palmier; F Tejerina; A Pinto; M Téllez; P Vázquez; A Cabello (Madrid, Spain)</i>
P060	Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BTC/FTC/TAF) in ART-naive patients: real-world data from the ICONA cohort <i>A Tavelli*; G Marchetti; A Vergori; E Quiros-Roldan; V Malagnino; F Vichi; M Lichtner; S Nozza; R Rossotti; L Sarmati; F Bai; A Di Biagio; A Antinori; A d'Arminio Monforte (Milan, Italy)</i>



Scientific Posters

Treatment Strategies - Target Populations: Experienced Patients

P061	Efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1: week 240 results of the phase III BRIGHT E study <i>J Aberg*</i> ; B Shepherd; M Wang; J Madruga; F Mendo Urbina; C Katlama; S Schrader; J Eron; S Chabria; A Clark; A Pierce; M Lataillade; P Ackerman (Brentford, UK)
P062	Meta-analysis of efficacy for DTG versus PI/r as second-line treatment in four randomised trials, 2662 participants <i>M Mirchandani; A Qavi; B Simmons; A Hill*</i> (Liverpool, UK)
P063	The impact of triggers of changes in sexual behaviour among persons living with HIV: Swiss Statement (U=U) and Covid-19 compared <i>K Hamusonde*</i> ; D Nicca; H Günthard; M Stöckle; K Darling; A Calmy; E Bernasconi; D Haerry; R Kouyos; A Rauch; L Salazar-Vizcaya (Bern, Switzerland)
P064	A multivariate analysis of the phase III BRIGHT E trial, through week 24, to identify predictors of virologic response to fostemsavir in heavily treatment-experienced people living with HIV <i>M Gartland*</i> ; X Wang; Q Liao; B Li; F Du; S Chabria; M Krystal; A Clark; M Lataillade; A Tenorio (Durham, NC, USA)
P065	Characterisation and outcomes of difficult-to-treat patients in an Italian cohort of PLWHIV starting modern ART regimens <i>R Gagliardini*</i> ; A Tavelli; S Rusconi; S Lo Caputo; V Spagnuolo; M Santoro; A Costantini; S Cicalini; F Maggiolo; A Giacomelli; G Burastero; C Agrati; G Madeddu; E Quiros Roldan; A d'Arminio Monforte; A Antinori; A Cozzi-Lepri (Roma, Italy)
P066	Metabolic and hepatic safety in ART-experienced PLWHIV switching to a DOR-based regimen versus rilpivirine: data from real life <i>P Maggi; E Ricci; C Martinelli; N Squillace*</i> ; G De Socio; G Orofino; C Molteni; A Masiello; B Menzaghi; F Vichi; E Pistarà; L Valsecchi; A Bitti; L Calza; G Pellicanò; A Cascio; L Taramasso; E Sarchi; K Falasca; O Bargiacchi; G Cenderello; A Di Biagio; P Bonfanti (Monza, Italy)
P067	Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 24-month (24M) analyses by age, race, sex, adherence and late presentation in a multi-country cohort study <i>B Trottier*</i> ; A Antinori; J De Wet; C Duvivier; H Elinav; S Esser; J Ghosn; J den Hollander; J Lambert; A Milinkovic; C Elliott; T Saifi; R Haubrich; D Thorpe; A Marongiu; C Miralles; S Schellberg; B van Welzen (Montreal, Canada)
P068	Real-world study with dolutegravir (DTG) plus rilpivirine (RPV) as STR (JULUCA®) in treatment-experienced HIV patients <i>C Hidalgo-Tenorio*</i> ; C Garcia Vallecillos; R Javier; M Lopez-Ruz; S Sequera; J Pasquau (Granada, Spain)

Treatment Strategies: Adherence

P069	Implementation of cabotegravir and rilpivirine long-acting (CAB+RPV LA): primary results from the CAB+RPV Implementation Study in European Locations (CARISEL) <i>B Van Welzen*</i> ; L Vandekerckhove; C Jonsson-Oldenbuettel; L Hocqueloux; M Ait-Khaled; G Bontempo; R DeMoor; J Scherzer; R D'Amico; N Barnes; M Hadi; E Low; S Anand; M Czarnogorski; C Gutner (Utrecht, Netherlands)
------	--



Scientific Posters

Treatment Strategies: Adherence (continued)

P070	Patient-reported outcomes after 152 weeks of HIV maintenance therapy with long-acting cabotegravir + rilpivirine in the phase IIIb ATLAS-2M study <i>V Chounta; E Overton; S Noe; S Swindells; E Negro; R D'Amico; C Harrington; S Vanveggel; R Van Solingen-Ristea; Y Wang; C Acupil; W Spreen* (Durham, NC, USA)</i>
P071	Adherence to HIV treatment in 2019: the COCOVIH study using the French national health insurance claims database <i>F PrevotEAU du Clary*; C Majerholc; D Zucman; J Livrozet; A Vallee; C Laurendeau; S Bouee (Toulouse, France)</i>

Treatment Strategies: Rapid ART

P074 Virtual	Rapid initiation of ART in Ukraine <i>S Vynohradova*; D Shevchenko; A Trotsenko; L Hetman; L Legkostup (Kyiv, Ukraine)</i>
P075 Virtual	Viral suppression at 1 year and rapid antiretroviral initiation in Guatemala <i>H Marroquín*; M Robles; D Ortíz; J Samayoa (Ciudad de Guatemala, Guatemala)</i>
P076	Rapid initiation of antiretroviral therapy (ART) with bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a tertiary hospital in Barcelona, Spain: a prospective clinical trial <i>A Ugarte; L De La Mora; I Chivite; E de Lazzari; E Fernandez; E Solbes; A Inciarte; J Ambrosioni; M Laguno; M Martinez-Rebollar; A González-Cordón; J Blanco; E Martinez; J Mallolas; B Torres* (Barcelona, Spain)</i>
P077	Patient-reported symptom outcomes following DTG/3TC use in a test-and-treat setting: results from the STAT Study <i>A Oglesby; J Matthews; K Angelis; P Leone; M Cupo; B Wynne; D Merrill*; C Nguyen; J Van Wyk; A Zolopa (Durham, NC, USA)</i>
P078	Impact of COVID-19 on the outcomes of rapid ART initiation among people living with HIV (PLWHIV): a multicentre study <i>Y Huang*; S Cheng; C Yang; H Sun; P Lu; C Liu; Y Lee; C Tsai; N Lee; B Liou; H Tang; C Lee; C Lin; C Hung (Hsin-Chu Country, Taiwan)</i>
P079	Rapid antiretroviral therapy initiation and acute HIV infection: current situation in a Latin American reference centre <i>M Santos; F Grimaldi; L Vignolo; F Pinilla Huayta; J Barletta; M Cabrini; O Cando; M Rolon* (Buenos Aires, Argentina)</i>
P080	Dolutegravir/lamivudine is clinically non-inferior to dolutegravir-based triple drug antiretroviral therapy: 1-year results of the DUALING real-world nationwide prospective matched cohort study <i>M Vasylyev*; F Wit; C Jordans; R Soetekouw; S van Lelyveld; G Kootstra; C Delsing; H Ammerlaan; M van Kasteren; E Brouwer; E Leyten; M Claassen; R Hassing; J den Hollander; M van den Berge; A Roukens; M van Vonderen; W Bierman; P Groeneveld; S Lowe; B van Welzen; O Richel; J Nellen; G van den Berk; M van der Valk; B Rijnders; C Rokx (Rotterdam, Netherlands)</i>



Scientific Posters

Treatment Strategies: Simplification

P081	Effectiveness of dolutegravir + lamivudine in real-world studies in people with HIV-1 with M184V/I mutations: a systematic review and meta-analysis <i>M Kabra; T Barber; C Allavena; A Marcelin; S di Giambenedetto; J Pasquau; N Gianotti; M Turner; C Harrison; T Wynne; G Verdier; C Parry; B Jones; C Okoli; J Priest*; E Letang (Durham, NC, USA)</i>
P082	Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat (DRV/c) in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens <i>D Podzamczar*; A Imaz; A Lopez-Lirola; H Knobel; M Masiá; J Berenguer; C Hernández; M Lagarde; A Gutierrez; A Curran; L Morano; M Montero-Alonso; J Troya; R Rigo; M Casadellà; A Navarro-Alcaraz; A Rivero (Badalona, Spain)</i>
P083	HIV-1 RNA blips, low-level viral replication and mean CD4+/CD8+ ratio during phase 3/3b cabotegravir + rilpivirine long-acting studies up to 152 weeks of therapy <i>C Latham*; L Garside; S Byrapuneni; C Smith; M St. Clair; V Van Eygen; S Griffith; R D'Amico; J van Lunzen; J van Wyk; W Spreen (Durham, NC, USA)</i>
P084	Real-world data from the prospective, multicentre study on the use of dolutegravir-based regimens (DBRs) in ART-naïve and experienced people living with HIV: 12-month results from the Russian TESLA study <i>S Kuznetsov*; S Minaeva; N Sizova; F Nagimova; E Orlova-Morozova; M Radzikhovskaya; V Shevchenko; A Maldonado; B Jones (Moscow, Russian Federation)</i>
P085	Safety and efficacy of switching people with HIV to dual treatment with 3TC/DTG and RPV/DTG in real life: results from the SCOLTA cohort <i>A De Vito*; E Ricci; G Orofino; L Taramasso; E Sarchi; C Costa; G Pelicanò; L Pagnucco; B Menzaghi; G De Socio; B Celesia; S Piconi; P Maggi; P Bonfanti; G Madeddu (Sassari, Italy)</i>
P086	Three-year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLWHIV: real-world data from the prospective German JUNGLE cohort <i>F Schabaz*; J Scherzer; S Schneeweiß; D Beer; K Ummard-Berger; R Pauli; C Wyen; H Hillenbrand; B Westermayer; K Dymek (Munich, Germany)</i>
P087	Systematic literature review of real-world experience with the two-drug regimen dolutegravir and lamivudine in people with HIV who would not have met inclusion criteria for the phase III clinical program <i>J Slim*; D Ward; S Schneider; M Kabra; G Verdier; B Jones; E Letang (Brentford, UK)</i>

Treatment Strategies: Switch Studies

P088	Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label B/F/TAF <i>C Orkin*; A Antinori; J Rockstroh; S Moreno Guillén; C Martorell; J Molina; A Lazzarin; F Maggiolo; Y Yazdanpanah; K Andreatta; H Huang; J Hindman; H Martin; J Baeten; A Pozniak (London, UK)</i>
P089	Switching to bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance: a phase IV randomised, open-label pilot study (PIBIK study) <i>C Iwuji*; L Waters; A Milinkovic; C Orkin; N Perry; N Dailey; Y To; S Bremner; A Geretti; D Churchill (Brighton, UK)</i>



Scientific Posters

Treatment Strategies: Switch Studies (continued)

P090	Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in Black and Asian participants from TANGO and SALSA: pooled 48-week data analyzed by race <i>P Kumar*</i> ; <i>D Hagins</i> ; <i>J Andrade-Villanueva</i> ; <i>P Lu</i> ; <i>E Adachi</i> ; <i>R Rubio</i> ; <i>T Lutz</i> ; <i>M Ait-Khaled</i> ; <i>R Grove</i> ; <i>B Wynne</i> ; <i>B Jones</i> ; <i>C Okoli (Brentford, UK)</i>
P091	Effectiveness and safety of dolutegravir-based two-drug regimens in a multicentre cohort in Spain <i>B Alejos</i> ; <i>I Suárez-García</i> ; <i>L Martín-Carbonero</i> ; <i>A Moreno-Zamora</i> ; <i>R Font</i> ; <i>J Portilla</i> ; <i>O Martínez</i> ; <i>M Omar</i> ; <i>D Vinuesa</i> ; <i>S Moreno*</i> ; <i>I Jarrin</i> ; <i>on behalf of the CoRIS Cohort (Madrid, Spain)</i>
P092	Characteristics of heavily treatment-experienced (HTE) people with HIV (PWHIV) in US clinical practice <i>J Eron</i> ; <i>M Dunbar</i> ; <i>J Radtchenko*</i> ; <i>J Gruber</i> ; <i>G Huhn</i> ; <i>G McComsey</i> ; <i>L Temme</i> ; <i>J Thompson</i> ; <i>R Elion (Chapel Hill, NC, USA)</i>
P093	Efficacy and safety of switching to dolutegravir plus rilpivirine in virologically suppressed older PLWHIV: pooled week 148 results from SWORD-1 and SWORD-2 <i>M Prakash*</i> ; <i>R Grove</i> ; <i>B Wynne</i> ; <i>J van Wyk</i> ; <i>B Jones</i> ; <i>A Clark (Brentford, UK)</i>
P094	Doravirine plus lamivudine (DOR/3TC) two-drug regimen as a maintenance antiretroviral therapy in controlled HIV-infected patients <i>P Perfezou</i> ; <i>N Hall</i> ; <i>J Duthe</i> ; <i>B Abdi</i> ; <i>S Seang</i> ; <i>A Marcelin</i> ; <i>C Katlama</i> ; <i>R Palich* (Paris, France)</i>
P095	Performance of dolutegravir-based two-drug regimens (DTG-2DR) in a large real-world cohort of people with HIV <i>C Bowman</i> ; <i>A Ambrose</i> ; <i>P Simoes</i> ; <i>K Florman</i> ; <i>T Kanitkar</i> ; <i>A Katiyar</i> ; <i>A Hunter</i> ; <i>J Hart</i> ; <i>T Barber* (London, UK)</i>
P096	Long-acting combination of cabotegravir plus rilpivirine: a picture of potential eligible HIV-positive individuals from the Italian ARCA cohort <i>A Cervo*</i> ; <i>A Russo</i> ; <i>D Di Carlo</i> ; <i>A De Vito</i> ; <i>L Fabeni</i> ; <i>S D'Anna</i> ; <i>L Duca</i> ; <i>A Colpani</i> ; <i>M Fois</i> ; <i>B Zauli</i> ; <i>G Mancarella</i> ; <i>A Carraro</i> ; <i>A Bezenchek</i> ; <i>A Cozzi-Lepri</i> ; <i>M Santoro (Modena, Italy)</i>
P097	Switch to bicitegravir in real-life settings in the ANRS-CO3-AquiVIH-NA cohort <i>O Leleux</i> ; <i>A Peyrouny-Mazeau</i> ; <i>A Perrier</i> ; <i>M Hessamfar</i> ; <i>G Le Moal</i> ; <i>D Neau</i> ; <i>H Wille</i> ; <i>E Lazaro</i> ; <i>B Castan</i> ; <i>P Duffau</i> ; <i>C Cazanave</i> ; <i>V Gaborieau</i> ; <i>L Wittkop</i> ; <i>F Bonnet* (Bordeaux, France)</i>
P098	Effectiveness of bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed: real-world data from the ICONA cohort <i>A d'Arminio Monforte*</i> ; <i>A Tavelli</i> ; <i>A Cingolani</i> ; <i>L Taramasso</i> ; <i>C Mussini</i> ; <i>S Piconi</i> ; <i>A Calcagno</i> ; <i>G Orofino</i> ; <i>S Cicalini</i> ; <i>A Castagna</i> ; <i>F Ceccherini-Silberstein</i> ; <i>A Gori</i> ; <i>G Guaraldi</i> ; <i>A Antinori (Milan, Italy)</i>
P099	Detection of 12-month immunological changes in patients randomised to switch either to BIC/TAF/FTC or DTG/3TC (DEBATE study) <i>A Cossarizza</i> ; <i>M Mattioli</i> ; <i>A Paolini</i> ; <i>A Neroni</i> ; <i>S De Biasi</i> ; <i>D Lo Tartaro</i> ; <i>R Borella</i> ; <i>L Fidanza</i> ; <i>L Gibellini</i> ; <i>B Beghetto</i> ; <i>E Roncaglia</i> ; <i>G Nardini</i> ; <i>M Menozzi</i> ; <i>G Cuomo</i> ; <i>M Di Gaetano</i> ; <i>G Orlando</i> ; <i>V Borghi</i> ; <i>C Mussini* (Modena, Italy)</i>
P100 Virtual	Durability of first-line antiretroviral treatment in Russia: retrospective study <i>N Sizova</i> ; <i>Y Plotnikova</i> ; <i>T Shimonova</i> ; <i>O Chernova</i> ; <i>E Ivanova</i> ; <i>A Kruglova</i> ; <i>V Achikyan* (Moscow, Russian Federation)</i>
P101	Efficacy and safety of dolutegravir and doravirine dual therapy in the context of antiretroviral therapy switch: 48 weeks analysis <i>M Trizzino*</i> ; <i>C Gioè</i> ; <i>A Medaglia</i> ; <i>P Di Carlo</i> ; <i>M Alfonso</i> ; <i>L Pipitò</i> ; <i>G Valenti</i> ; <i>A Cascio (Palermo, Italy)</i>



Scientific Posters

Treatment Strategies: Switch Studies (continued)

P102 Virtual	One year of follow-up after switching to doravirine in treatment-experienced people living with HIV: a real-world cohort study <i>V Lanting*</i> ; <i>P Oosterhof</i> ; <i>D Ait Moha</i> ; <i>R van Heerde</i> ; <i>M Kleene</i> ; <i>J Stalenhoef</i> ; <i>M de Regt</i> ; <i>S Vrouenraets</i> ; <i>G van den Berk</i> ; <i>K Brinkman (Amsterdam, Netherlands)</i>
P103	ART regimen persistence among treatment-experienced patients with HIV switching to a MTR or STR since 2018 <i>B Chastek</i> ; <i>A Anderson</i> ; <i>N Webb</i> ; <i>M Rock</i> ; <i>J Gruber</i> ; <i>S Majethia</i> ; <i>W Zachry*</i> ; <i>J Cohen</i> ; <i>A Colson (Foster City, CA, USA)</i>
P104	Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a single centre in Portugal <i>A Gorgulho*</i> ; <i>I Vaz-Pinto</i> ; <i>C Santos</i> ; <i>M Guimaraes</i> ; <i>V Castro (Alcabideche, Portugal)</i>
P105	Effectiveness and tolerability of the bictegravir/emtricitabine/tenofovir alafenamide regimen in a cohort of HIV-1 infected treatment experienced adult patients: an observational retrospective single-centre study <i>M Ceccarelli*</i> ; <i>M Ricciardetto</i> ; <i>B Bellocchi</i> ; <i>L Todaro</i> ; <i>V Boscia</i> ; <i>A Campanella</i> ; <i>G Nunnari</i> ; <i>B Cacopardo</i> ; <i>B Celesia (Catania, Italy)</i>
P106	Effectiveness and safety of doravirine from a real-world HIV cohort: DORWINS study <i>N Espinosa Aguilera*</i> ; <i>M Mejías Trueba</i> ; <i>A Gutiérrez Valencia</i> ; <i>S Llaves Flores</i> ; <i>M Herrero Romero</i> ; <i>C Sotomayor de la Piedra</i> ; <i>C Roca Oporto</i> ; <i>M Rodriguez Hernandez</i> ; <i>L Lopez Cortes (Sevilla, Spain)</i>
P107	Efficacy and safety of switching to co-formulated DOR/TDF/3TC in virologically suppressed HIV-1-infected patients: early experience from a single Italian centre <i>F Lagi</i> ; <i>G Formica*</i> ; <i>F Ducci</i> ; <i>S Tekle Kiros</i> ; <i>M Pozzi</i> ; <i>F Bartalesi</i> ; <i>P Corsi</i> ; <i>C Malcontenti</i> ; <i>G Sterrantino</i> ; <i>A Bartoloni (Florence, Italy)</i>
P108	Doravirine used as a fixed combination doravirine/lamivudine/tenofovir disoproxil, among persons living with HIV at switch and start: real-life data from the Croatian HIV cohort <i>S Zekan*</i> ; <i>J Begovac (Zagreb, Croatia)</i>
P109	Treatment-experienced HIV-1 infected patients under salvage regimen with dolutegravir and boosted darunavir: a real-life scenario <i>L Moura*</i> ; <i>C Batista</i> ; <i>F Duarte</i> ; <i>I Neves</i> ; <i>R Correia de Abreu</i> ; <i>J Laranjinha (Matosinhos, Portugal)</i>

Treatment Strategies: Other

P110	HIV-2: the global experience of a Portuguese centre since the beginning of the epidemic <i>M Pereira*</i> ; <i>J Borralho</i> ; <i>J Vasconcelos</i> ; <i>J Alves</i> ; <i>S Peres</i> ; <i>A Miranda</i> ; <i>T Baptista</i> ; <i>I Antunes</i> ; <i>F Borges</i> ; <i>K Mansinho (Lisbon, Portugal)</i>
P111	High proportion of born-abroad MSM acquire HIV after migration in France: first results from the ANRS-MIE GANYMEDE study <i>A Arias Rodriguez</i> ; <i>L Assoumou</i> ; <i>O Rousset Torrente</i> ; <i>C Lascoux-Combe</i> ; <i>J Ghosn</i> ; <i>T Chiarabini</i> ; <i>A Velter</i> ; <i>M Ben Mechlia</i> ; <i>L Béniguel</i> ; <i>M Duracinsky</i> ; <i>V Supervie</i> ; <i>R Palich* (Paris, France)</i>
P112	A pooled analysis of eight clinical studies suggests a link between influenza-like adverse events and pharmacodynamics of the toll-like receptor 7 agonist vesatolimod <i>S Riddler</i> ; <i>Y Cai</i> ; <i>E Vendrame</i> ; <i>Y Zheng</i> ; <i>L Zhang</i> ; <i>D Verrill</i> ; <i>X Liu</i> ; <i>D SenGupta*</i> ; <i>D Lim (Foster City, CA, USA)</i>



Scientific Posters

Treatment Strategies: Other (continued)

P113	High rates of central nervous system adverse events among patients on dolutegravir-based regimens in Uganda <i>E Laker Odongpiny*; E Katana; J Owori; K Seden; D Meya; M Nicol; M Kesby; M Holden; D Sloan; C Sekaggya (Kampala, Uganda)</i>
P114	Effect of 12-week cART on gut mucosal immunity and microbiome in primary HIV infection (PHI) <i>C Tincati*; V Bono; M Falleni; D Tosi; V Yellenki; R Rovito; S Rusconi; A Giacomelli; A Muscatello; S Dispinseri; A d'Arminio Monforte; A Calcagno; S Nozza; A Gori; G Marchetti (Milan, Italy)</i>
P116	Overcoming barriers and achieving optimal implementation of cabotegravir and rilpivirine long-acting (CAB+RPV LA): staff study participant (SSP) results from the CAB+RPV Implementation Study in European Locations (CARISEL) <i>L Slama*; M Crusells-Canales; J Olalla; R DeMoor; M Ait-Khaled; S Dakhia; H Van Mechelen; A Hamilton; M Hadi; D Filipenko; F Brown; E Low; C Gutner; M Czarnogorski (Paris, France)</i>
P117	Two-year outcomes of dolutegravir (DTG) + lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort <i>D Beer*; J Scherzer; S Noe; S Scholten; C Wyen; N Postel; O Degen; M Sabranski; B Westermayer; K Dymek (Aachen, Germany)</i>
P118	Contributions to HIV cure research from Africa: a systematic review <i>G Kyei*; E Bonney; J Aboagye; H Lamptey; C Abana; A Boateng; S Kaminta; P Wormenor; C Forfoe; C Bortey; P Nartey; D Attoh; P Boakye; K Sedzro (Accra, Ghana)</i>
P119	HIV resistance patterns in a cohort of adults living with HIV failing first-line efavirenz-based antiretroviral therapy in South Africa <i>B Bosch*; S Sokhela; J Woods; E Bhaskar; K Moller; N Manentsa; F Venter (Johannesburg, South Africa)</i>
P120	HIV testing training for non-HIV specialists in a tertiary hospital: change in attitudes and rates of HIV screening <i>A García García*; J Martínez Sanz; M Vivancos Gallego; C Cano; B Romero; M Sánchez Conde; M Vélez Díaz-Pallarés; M González Vázquez; F Gea Rodríguez; J Galán Montemayor; M Pérez Elías (Madrid, Spain)</i>
P121	Knowledge, attitudes, and practices in chronic inflammation and cardiovascular risk associated with HIV infection in Spain <i>S Serrano Villar*; J Moltó; M Montero-Alonso; C Diaz Torné; L Pérez de Isla (Madrid, Spain)</i>
P122	A retrospective, multicentre study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real-world setting in Belgium <i>R Nasreddine*; E Florence; J Yombi; S Henrard; G Darcis; J Van Praet; L Vandekerckhove; S Allard; R Demeester; P Messiaen; N Ausselet; M Delforge; S De Wit (Brussels, Belgium)</i>
P123	Perceptions of cabotegravir and rilpivirine long-acting (CAB+RPV LA) from patients in the CAB+RPV Implementation Study in European Locations (CARISEL) <i>T Lutz; E Jeanmaire; J Portilla; J Scherzer; R Trehan; M Pascual-Bernáldez; R DeMoor; M Ait-Khaled; M Hadi; S Anand; E Low; M Czarnogorski; C Gutner* (Durham, NC, USA)</i>
P124	Digital emergency healthcare seeking behaviour of Ukrainian refugees living with HIV <i>C Jordans*; M Vasylyev; C Rokx (Rotterdam, Netherlands)</i>



Scientific Posters

Treatment Strategies: Other (continued)

P125 Virtual	The application of HIV-1 proviral DNA in patients with low-level viraemia under antiretroviral therapy <i>S Lv*</i> ; <i>R Bai</i> ; <i>M Dai</i> ; <i>W Hua</i> ; <i>R Xin</i> ; <i>L Dai</i> (Beijing, China)
P126	Real-world utilisation of doravirine among people living with HIV in England (DRIVE-REAL) <i>C O'Halloran*</i> ; <i>Y Gilleece</i> ; <i>I Williams</i> ; <i>S Leung</i> ; <i>V Canuto</i> ; <i>C McAlpine</i> ; <i>S Ross</i> ; <i>C Norcross</i> ; <i>S Gaffney</i> ; <i>N Siani</i> ; <i>W Hickey</i> ; <i>A Moore</i> ; <i>O Rajkovic-Hooley</i> ; <i>A Milinkovic</i> (London, UK)
P127	Association between fentanyl use and virologic suppression in an HIV-infected cohort of people who use/inject drugs (PWID): results from a bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) switch study <i>B Conway*</i> ; <i>S Yi</i> ; <i>S Sharma</i> ; <i>R Yung</i> ; <i>D Truong</i> (Vancouver, Canada)
P128	HIV testing in an infectious diseases unit: can we follow the guidelines? <i>L Buchanan*</i> ; <i>D Bell</i> ; <i>S Debono</i> (Glasgow, UK)
P129	Real-life monocentric Biktarvy cohort from Perugia <i>S Benedetti*</i> ; <i>D Altobelli</i> ; <i>G De Socio</i> ; <i>A Lanzi</i> ; <i>G Gamboni</i> ; <i>D Francisci</i> (Perugia, Italy)
P130	Clinical experience using dolutegravir + lamivudine in Glasgow <i>M Debono*</i> ; <i>K Ocker</i> ; <i>S Shepherd</i> ; <i>D Bell</i> (Glasgow, UK)

Opportunistic Infections

P131	Changes to LTBI screening in new diagnoses of HIV during the COVID-19 pandemic <i>M Henderson*</i> ; <i>S Ojinnaka</i> ; <i>L Garvey</i> ; <i>N Mackie</i> ; <i>B Mora-Peris</i> (London, UK)
P132	Latent tuberculosis infection and associated risk factors among people living with HIV and HIV-uninfected individuals in Lithuania <i>E Matulyte*</i> ; <i>Z Kancauskiene</i> ; <i>A Kausas</i> ³ <i>J Urboniene</i> ; <i>V Lipnickiene</i> ; <i>I Razmiene</i> ; <i>J Kopeykiniene</i> ; <i>B Jonaityte</i> ; <i>A Eimutiene</i> ; <i>G Arstikaitiene</i> ; <i>A Lisinskaite</i> ; <i>T Gudaitis</i> ; <i>S Raudonis</i> ; <i>E Danila</i> ; <i>D Costagliola</i> ; <i>R Matulionyte</i> (Vilnius, Lithuania)
P133 Virtual	Pharmacovigilance and drug safety trainings to increase tuberculosis (TB) preventive treatment (TPT) for tuberculosis in Zimbabwe <i>J Jokwiro*</i> ; <i>N Kawaza Chekudambune</i> ; <i>K Sithole</i> ; <i>B Dube</i> ; <i>C Sandy</i> ; <i>M Ncube</i> ; <i>R Mubau</i> ; <i>C Gwanzura</i> ; <i>K Ndlovu</i> ; <i>A Nyambo</i> (Harare, Zimbabwe)
P134 Virtual	Rapid efficiencies in policy adoption through policy influence plan and consultative engagements revolutionalise the TB preventive therapy (TPT) landscape in Zimbabwe <i>J Jokwiro*</i> ; <i>N Kawaza Chekudambune</i> ; <i>K Sithole</i> ; <i>B Dube</i> ; <i>C Sandy</i> ; <i>M Ncube</i> ; <i>C Gwanzura</i> ; <i>R Mubau</i> ; <i>A Nyambo</i> (Harare, Zimbabwe)
P135 Virtual	Closing the science-to-service gap by increasing TB preventive therapy (TPT) uptake using the choice architecture tuberculosis preventive therapy (CAT) prescriptive stickers <i>J Jokwiro*</i> ; <i>N Kawaza Chekudambune</i> ; <i>K Sithole</i> ; <i>B Dube</i> ; <i>C Sandy</i> ; <i>M Ncube</i> ; <i>R Mubau</i> ; <i>C Gwanzura</i> ; <i>A Nyambo</i> ; <i>K Ndlovu</i> (Harare, Zimbabwe)
P136 Virtual	Effects of incentivizing TB contact investigation and linkage to treatments <i>B Dube*</i> ; <i>N Chekudambune-Kawaza</i> ; <i>J Jokwiro</i> ; <i>K Sithole</i> ; <i>C Sandy</i> ; <i>M Ncube</i> ; <i>C Gwanzura</i> ; <i>R Mubau</i> ; <i>K Ndlovu</i> ; <i>N Siziba</i> (Harare, Zimbabwe)



Scientific Posters

Opportunistic Infections (continued)

P137 Virtual	Tailored support visits to improve screening rates for cryptococcal meningitis and tuberculosis during early implementation of the advanced HIV disease package of care in Zimbabwe <i>G Saemisch; T Chirindo*; T Maparo; C Giyava; A Moore; I Amamilo; N Kawaza (Harare, Zimbabwe)</i>
P138	Utilizing electronic communications for clinical mentorship to improve optimal treatment rates for cryptococcal meningitis in Malawi <i>G Saemisch; Y Gumulira*; R Nyirendra; B Wilson; P Nyasulu; D Telela; E Matupa; T Mwenifumbo; A Moore; I Amamilo (Lilongwe, Malawi)</i>

Co-morbidities and Complications of Disease and/or Treatment: Ageing

P140	Age-related differences in quality of life outcomes of people living with HIV <i>A Clark; C Donatti; N Nwokolo; F Hennessy*; A McMillan; O Carter; T Holbrook; J Priest (Bollington, UK)</i>
P141	Re-framing how frailty is identified, diagnosed and managed among people living with HIV: exploratory perspectives from clinical practice <i>T Barber*; T Levett; D Brown; P Pristera; N Galbraith; B Patterson; J Williams; M Boffito (London, UK)</i>
P142 Virtual	Frailty status and associated factors among older PLWHIV in Southern Ethiopia <i>E Woldeamayyat*; N Clair-Sullivan; A Kassa; T Gari; K Gutema; N Chea; K Wubshet; N Bogale; A Asefa; J Vera (Hawassa, Ethiopia)</i>
P143	Effect of online education on physician knowledge and confidence regarding the impact of inflammation and the failure to recover CD4 T cell counts in people living with HIV <i>J Duffey*; S Voorn; C Ní Cheallaigh; M Young Karris; P Hunt; G Guaraldi (New York, NY, USA)</i>
P144	Are iron metabolism parameters and relative telomere length possible biomarkers of ageing in HIV-infected patients? <i>G Dragovic Lukic*; S De Luka; A Trbovich; B Obradovic; D Jevtovic; B Toljic; J Milasin (Belgrade, Serbia)</i>

Co-morbidities and Complications of Disease and/or Treatment: Cardiovascular

P145	Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study <i>R Martin-Iguacel*; M Vazquez-Friol; J Burgos; A Bruguera; J Reyes-Urueña; S Moreno-Fornés; J Aceitón; Y Díaz; P Domingo; M Saumoy; H Knobel; D Dalmau; B Borjabad; I Johansen; J Miro; J Casabona; J Llibre (Badalona, Spain)</i>
P146	Prevalence of cardiovascular disease (CVD) and comparison of risk category predictions of Systemic Coronary Risk Evaluation 2 (SCORE2) and four other CVD risk calculators among PLWHIV in Turkey <i>E Tükenmez Tigen*; D Gökengin; H Özkan Özdemir; H Akalın; B Kaya; A Deveci; A İnan; D İnan; A Altunsoy; A Özel; İ Karaoğlan; H Eraksoy; T Demirdal; T Yıldırım; S Birengel; A İnci; A Nazlı; B Kayaaslan; S Sayın Kutlu; Ç Ataman Hatipoğlu; Y Esen; T Koç; V Korten (Istanbul, Turkey)</i>
P147	Study of the cardiovascular disease risk in people living with HIV-1 in Portugal <i>F Palha*; M Casella; M Caixas Lima; F Roxo; S António; C Piñeiro; J Soares; R Pinho; L Pedro; J Oliveira; F Cunha; R Pereira; P Proença; J Ferreira; A Pimenta Castro; C Delgado (Lisbon, Portugal)</i>
P148	Evaluation of lipid profile and intima media thickness in HIV-experienced patients treated with PI-based regimens versus PI-sparing regimens <i>S Martini*; M Pisaturo; P Maggi; N Coppola (Napoli, Italy)</i>



Scientific Posters

Co-morbidities and Complications of Disease and/or Treatment: Metabolic

P149	Long-term risks of clinical obesity in the ADVANCE, NAMSAL and VISEND trials <i>A Hill*</i> ; <i>M Mirchandani</i> ; <i>B Simmons</i> ; <i>S Sokhela</i> ; <i>F Venter (Liverpool, UK)</i>
P150	Understanding changes in metabolic parameters switching to 2DR or 3DR integrase strand inhibitors (INSTIs) <i>S Degroote</i> ; <i>S Vanherrewewege</i> ; <i>E Tobback</i> ; <i>E Caluwé</i> ; <i>L Vincke</i> ; <i>E Blomme</i> ; <i>L Vandekerckhove</i> ; <i>M De Scheerder* (Ghent, Belgium)</i>
P151	Genetic contribution to weight gain after initiation of antiretroviral therapy in treatment-naïve patients with HIV <i>J Berenguer*</i> ; <i>I Jarrín</i> ; <i>J Bellón</i> ; <i>C Díez</i> ; <i>M Jiménez-Sousa</i> ; <i>R Navarro-Soler</i> ; <i>J Iribarren</i> ; <i>I Suárez-García</i> ; <i>C Amador</i> ; <i>A Curran</i> ; <i>F Villarroya</i> ; <i>P Domingo</i> ; <i>S Resino (Madrid, Spain)</i>
P152	Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults living with HIV: a multicentre prospective cohort study <i>J Martínez-Sanz</i> ; <i>S Serrano-Villar</i> ; <i>A Muriel</i> ; <i>L García Fraile</i> ; <i>E Orviz</i> ; <i>Á Mena de Cea</i> ; <i>A Campins</i> ; <i>S Moreno* (Madrid, Spain)</i>
P153	Factors associated with weight loss or stable weight after continuing or switching to a doravirine-based regimen <i>C Orkin*</i> ; <i>J Koethe</i> ; <i>P Kumar</i> ; <i>Z Xu</i> ; <i>R Plank</i> ; <i>W Greaves</i> ; <i>P Sklar</i> ; <i>R Lahoulou (London, UK)</i>
P154	Progression or regression of metabolic-associated fatty liver disease in relation to INSTI/TAF exposure <i>J Milic</i> ; <i>S Renzetti</i> ; <i>F Motta</i> ; <i>J Bischoff</i> ; <i>A Dessilani</i> ; <i>J Conti</i> ; <i>F Medioli</i> ; <i>M Del Monte</i> ; <i>B Lebouche</i> ; <i>S Al Hinai</i> ; <i>M Deschenes</i> ; <i>S Calza</i> ; <i>C Mussini</i> ; <i>J Rockstroh</i> ; <i>G Guaraldi*</i> ; <i>G Sebastiani (Modena, Italy)</i>
P155	Liver enzymes levels, metabolic and renal profile modifications after switching from TDF- to TAF-based regimens among ART-experienced PLWHIV in the ICONA cohort <i>M Polisenio</i> ; <i>S Lo Caputo</i> ; <i>A Tavelli*</i> ; <i>R Gagliardini</i> ; <i>L Gazzola</i> ; <i>A Saracino</i> ; <i>T Santantonio</i> ; <i>N Squillace</i> ; <i>M Puoti</i> ; <i>S Cicalini</i> ; <i>A Antinori</i> ; <i>A D'Arminio Monforte</i> ; <i>A Cozzi-Lepri (Milan, Italy)</i>
P156	Risk factors associated with 10% weight change in treatment-naïve and treatment-experienced people living with HIV initiating or switching to an NNRTI- or INSTI-based antiretroviral therapy in four large cohort studies <i>O Robineau</i> ; <i>A Marongiu</i> ; <i>H Stellbrink</i> ; <i>J Meynard</i> ; <i>J Brunetta</i> ; <i>D Turner*</i> ; <i>A D'Arminio Monforte</i> ; <i>M Castaño-Carracedo</i> ; <i>B van Welzen</i> ; <i>L Williams</i> ; <i>R Haubrich</i> ; <i>M Heinzkill</i> ; <i>S Sahali</i> ; <i>S Schreiber</i> ; <i>J Gruber</i> ; <i>C Cohen</i> ; <i>S Esser (Tel-Aviv, Israel)</i>
P157	Socio-economic deprivation, obesity, and diabetes mellitus in people of African ancestry living with HIV in South London <i>L Dominguez-Dominguez*</i> ; <i>S Tariq</i> ; <i>L Cechin</i> ; <i>L Hamzah</i> ; <i>J Fox</i> ; <i>V Kolodin</i> ; <i>H Lempp</i> ; <i>L Goff</i> ; <i>D Onyango</i> ; <i>L Campbell</i> ; <i>F Post (London, UK)</i>
P158	Results of Hepmarc: a 96-week feasibility trial of add-on maraviroc in people with well-controlled HIV and NAFLD <i>D Bradshaw*</i> ; <i>I Abramowicz</i> ; <i>S Bremner</i> ; <i>S Verma</i> ; <i>Y Gilleece</i> ; <i>S Kirk</i> ; <i>M Nelson</i> ; <i>R Housman</i> ; <i>H Miras</i> ; <i>C Orkin</i> ; <i>A Fox</i> ; <i>M Curnock</i> ; <i>L Jennings</i> ; <i>M Gompels</i> ; <i>E Clarke</i> ; <i>R Robinson</i> ; <i>P Lambert</i> ; <i>D Chadwick</i> ; <i>N Perry (Brighton, UK)</i>
P159	HIV-associated wasting in the era of weight gain <i>M Wohlfeiler</i> ; <i>R Weber</i> ; <i>L Brunet</i> ; <i>J Siddiqui</i> ; <i>M Harbour*</i> ; <i>A Phillips</i> ; <i>B Hayward</i> ; <i>J Fusco</i> ; <i>R Hsu</i> ; <i>G Fusco (Miami, FL, USA)</i>



Scientific Posters

Co-morbidities and Complications of Disease and/or Treatment: Metabolic (continued)

P160	Comparison of HIV-associated wasting definitions in the OPERA cohort <i>M Wohlfeiler; R Weber; L Brunet; J Siddiqui; M Harbour*; A Phillips; B Hayward; J Fusco; R Hsu; G Fusco (Miami, FL, USA)</i>
P161	Metabolic effects of switching to tenofovir alafenamide/emtricitabine/bictegravir (B/F/TAF) from tenofovir difumarate (TDF) or tenofovir alafenamide (TAF) sparing regimens: METABIC study <i>C Busca; D Ortega; L Martín Carbonero; R Mican; L Ramos; M Valencia; R Montejano; M Montes; M Díaz-Almirón; A Delgado; J Bernardino* (Madrid, Spain)</i>
P162	Liver enzyme variation after switching to emtricitabine/tenofovir alafenamide/bictegravir is associated with glucose increase in a real-life cohort <i>N Squillace*; E Ricci; P Maggi; B Menzaghi; G De Socio; G Orofino; B Celesia; A Bandera; E Salomoni; A Di Biagio; L Taramasso; S Piconi; E Sarchi; L Valsecchi; G Pellicanò; G Cenderello; P Bonfanti (Monza, Italy)</i>
P163	With or without TAF? What is the difference? Data from a real-life setting <i>N Squillace*; L Taramasso; G Orofino; P Maggi; B Menzaghi; S Piconi; G De Socio; E Sarchi; L Valsecchi; B Celesia; F Vichi; G Pellicanò; G Cenderello; K Falasca; E Ricci; A Di Biagio; P Bonfanti (Monza, Italy)</i>
P165	Lipid changes in real-world studies with the two-drug regimen dolutegravir and lamivudine (DTG + 3TC) in people with HIV-1: a systematic literature review <i>E Letang*; J Lo; A Milinkovic; F Maggiolo; S di Giambenedetto; C Mussini; I Ungan Yörük; C Henegar; J Priest; B Young; M Kabra; B Jones (Madrid, Spain)</i>
P166	New-onset diabetes in persons with HIV on BIC/FTC/TAF in real-world clinical practice <i>M Vivancos-Gallego; A Moreno-Zamora; M Perez-Elias*; S Del Campo; J Casado; S Serrano-Villar; J Martinez-Sanz; R Ron; M Sanchez-Conde; B Fernandez-Felix; S Fernandez-Garcia; M Velez-Diaz-Pallares; J Galan; S Moreno-Guillen (Madrid, Spain)</i>
P167	Prevalence of dyslipidaemia and diabetes mellitus in people living with HIV and possible association with antiretroviral drug regimen: an 8 year follow-up study <i>T Dorner; T Obersteiner*; H Schalk; K Pichler; I Grabovac (Vienna, Austria)</i>

Co-morbidities and Complications of Disease and/or Treatment: Neurological

P168	Drug-related neuropsychiatric adverse events across phase III/IIIb studies of long-acting cabotegravir + rilpivirine through week 48 <i>E Elliot*; P Teichner; S Dakhia; J Polli; P Patel; L Garside; S Byrapuneni; S Thiagarajah; R D'Amico; R Van Solingen-Ristea; E Birmingham; B Baugh; J van Wyk (Madrid, Spain)</i>
P169 Virtual	Evaluation of the psychometric properties of health-related quality of life patient-reported outcome measures for use in people living with HIV with cognitive symptoms <i>K Alford*; S Daley; S Banerjee; D Trotman; E Hamlyn; J Vera (Brighton and Hove, UK)</i>
P170 Virtual	Understanding the lived experience research priorities for improving quality of life in people living with HIV and cognitive impairment <i>K Alford*; J Hammond; J Vera; S Daley (Brighton and Hove, UK)</i>
P171	Effects of an online-based cognitive stimulation training as a preventive programme in patients with HIV: a proof of concept study <i>J Cano-Smith; A Gonzalez-Baeza; G Rua-Cebrian; R Mican; J Bernardino; C Busca; L Martin-Carbonero; J Gonzalez; V Moreno; E Valencia; M Montes; L Ramos; I Perez-Valero* (Cordoba, Spain)</i>



Scientific Posters

Co-morbidities and Complications of Disease and/or Treatment: Neurological (continued)

P172 **The effects of switching from dolutegravir/abacavir/lamivudine to bicitegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study**
B Rossetti; M Ferrara; L Taramasso; F Bai; F Lombardi; N Ciccarelli; M Durante; F Alladio; I Rancan; F Montagnani; A Di Biagio; A d'Arminio Monforte; M Zazzi; M Fabbiani (Siena, Italy)*

P173 **Sleep health of Nigerian adults living with HIV: looking beyond the absence of disease**
A Osiyemi; E Owoaje; J Mundt; B Taiwo (Ibadan, Nigeria)*

Co-morbidities and Complications of Disease and/or Treatment: Mental Health Disorders

P174 **Resolution of neuropsychiatric adverse events after switching to a doravirine-based regimen in the open-label extensions of the DRIVE-AHEAD and DRIVE-FORWARD trials**
G Moyle; H Wan; F Meng; R Plank; P Sklar; R Lahoulou (London, UK)*

P175 **Defining the cascade of mental healthcare: increased prevalence of depression and lack of access to care for people ageing with HIV**
H Okhai; A Winston; F Post; M Boffito; P Mallon; J Vera; I Williams; M Sachikonye; M Johnson; J Anderson; C Precht; C Sabin (London, UK)*

P176 **Psychological wellbeing and sleep in human immunodeficiency virus (HIV) - a retrospective analysis of assessment and interventions within HIV services in the UK and Ireland (UKI)**
N Galbraith; J Paparello; S Gyampo; K Carroll; A Brown (London, UK)*

Co-morbidities and Complications of Disease and/or Treatment: Other

P177 **Measuring what matters: how do we assess sleep in HIV care?**
M Croston; K Bourne; E Hurt; N Galbraith; M Hayter (London, UK)*

P178 **Pre-ART platelet-to-lymphocyte ratio and the risk of serious non-AIDS events, AIDS events and mortality in PLWHIV starting first-line ART**
P Saltini; A Cozzi-Lepri; G Bozzi; G Marchetti; L Taramasso; S Mazzanti; V Rizzo; A Antinori; C Mussini; A Gori; A D'Arminio Monforte; A Bandera (Milan, Italy)*

P179 **Lymphogranuloma venereum is highly prevalent among rectal chlamydia infections and HIV-positive men who have sex with men in Austria: findings from an observational multicentre study**
D Chromy; B Sadoghi; I Gasslitter; M Skocic; A Okoro; K Grabmeier-Pfistershammer; B Willinger; W Weninger; A Öllinger; M Sarcletti; G Stary; W Bauer (Vienna, Austria)*

P180 **Osteoporosis among older persons living with HIV in Kenya: baseline results from the BFTAF elderly switch study**
L Ombajo; J Penner; J Nkuranga; R Wanjohi; J Mecha; M Mburu; F Ndinya; S Eshiwani; S Wahome; E Otieno; A Pozniak; S Bhagani (Nairobi, Kenya)*

P181 **Lack of prediction of fragility fractures by risk assessment tools in a cohort of people with HIV**
P Vizcarra; A Moreno; M Vivancos; A Muriel García; J González-García; S Moreno; S Ibarra Ugarte; J Olalla Sierra; D Dalmau; J Casado (Madrid, Spain)*

P182 **Neurosyphilis in people living with HIV: current incidence and diagnostic approach**
P Vizcarra; A Moreno; M Vivancos; J del Pino; S Martín-Colmenarejo; A Abad; J Casado (Madrid, Spain)*



Scientific Posters

Co-morbidities and Complications of Disease and/or Treatment: Other (continued)

P183	Evolution of TDF-associated tubular dysfunction after switching to tenofovir alafenamide (TAF) in people living with HIV <i>P Vizcarra; J del Rey; C Santiuste; A Moreno*; S Gomez-Maldonado; J Casado (Madrid, Spain)</i>
P184	HIV-related stigma and its relationship to quality of life among people living with HIV enrolled in the Swiss HIV Cohort Study <i>J Damas; A Justice; D Satre; M Silverberg; J Sterne; A Wrona; K McGinnis; F Kidwai-Khan; E Kampouri; D Jackson-Perry; D Braun; M Cavassini; K Darling* (Lausanne, Switzerland)</i>
P185	Increasing incidence of syphilis among people living with HIV in Croatia during the COVID-19 years 2020 and 2021 <i>J Begovac; V Romih Pintar; L Mocibob; N Vrsaljko; N Bogdanic; S Zekan*; A Atelj; D Lukas; O Dakovic Rode (Zagreb, Croatia)</i>
P186	Pancreatic cancer in people living with HIV: an emerging concern? <i>S Chawki*; N Lourenço; G Hamet; A Brun; O Bouchaud; J Bottero; P Sellier; J Molina (Paris, France)</i>
P187	Prevalence of Mycoplasma genitalium infection and resistance-associated mutations to macrolides and fluoroquinolones among people living with HIV and people on pre-exposure prophylaxis in Taiwan <i>Y Su*; L Su; W Liu; H Sun; W Liu; K Lin; Y Huang; G Chen; S Chang; C Hung (Taipei, Taiwan)</i>
P188	Identification of quality-of-life alterations in PLWHIV in routine practice: benefit of the OCTAVE self-administered questionnaire <i>L Slama*; F Bastides; O Robineau; J Leporrier; G Barriere; E Estrabaud; V Pourcher; E Piet (Paris, France)</i>
P189	Quality of sleep in people living with HIV (PLWHIV) in the era of highly active antiretroviral treatment (HAART) <i>V Petrakis; P Panagopoulos*; N Papanas; G Trypsianis; P Steiropoulos; D Papazoglou (Alexandroupolis, Greece)</i>
P190	Oropharyngeal infection due to HPV in people living with HIV (PLHIV) <i>C Hidalgo Tenorio*; L Benitez Cejas; I Calle; R Moya; P Gomez Ronquillo; J Lopez Hidalgo; J Rodriguez (Granada, Spain)</i>
P191	Detection of <i>Treponema pallidum</i> DNA among men who have sex with men who presented with early syphilis <i>T Wu*; L Su; S Chang; H Sun; W Liu; Y Huang; W Liu; K Lin; C Hung (Taipei City, Taiwan)</i>
P192	A qualitative exploration of HIV stigma and its impact on accessing healthcare <i>D Jackson-Perry; C Le Saux; I Gilles; C Storari; O Keserue Pittet; O Nawej Tshikung; E Cart; M Cavassini; K Darling* (Lausanne, Switzerland)</i>
P193	Is HIV still a barrier to sex for people living with HIV in the UK? <i>C Tugulu*; N Ahmed; P Bullemor-Day; D Weston; J Ashby (London, UK)</i>
P194	Effect of online education on physician knowledge and confidence regarding the impact that stigma has on health outcomes in people living with HIV <i>J Duffey*; S Voorn; C Ní Cheallaigh; M Young Karris; J Rockstroh (Matlock, UK)</i>
P195	Knowledge of STIs and HIV among people with and without HIV: where are we now? <i>A Colpani*; A De Vito; B Zauli; B Menzaghi; A Calcagno; B Celesia; M Ceccarelli; G Nunnari; G De Socio; A Di Biagio; N Leoni; G Angioni; S Babudieri; G Madeddu (Sassari, Italy)</i>



Scientific Posters

Co-morbidities and Complications of Disease and/or Treatment: Other (continued)

P196	Increased serum APOC3 in syphilitic patients can predict the absence of Jarisch-Herxheimer reaction after benzathine penicillin treatment <i>H Tsai* (Kaohsiung, Taiwan)</i>
P197	A curious tale: quetiapine toxicity with cobicistat but not with ritonavir in a person living with HIV <i>A Duncan*; T Syme; K Mackie; L Grannell; S Lewin (Melbourne, Australia)</i>
P198	Efficacy of 2DR HIV therapy in polypathological patients with polypharmacy <i>L Pagnucco*; R Bruno; R Gulminetti (Pavia, Italy)</i>
P199	Could we consider U=U as a potential driver of new syphilis infection in HIV population during the Covid-19 pandemic? <i>L Todaro*; B Bellocchi; M Paternò Raddusa; S Pulvirenti; A Guarneri; V Boscia; G Nunnari; B Cacopardo; M Ceccarelli; B Celesia (Catania, Italy)</i>

Viral Hepatitis

P200	The path to hepatitis C elimination: analysis of the epidemic in 110 countries <i>K Heath; A Hill* (Liverpool, UK)</i>
P201	Coinfection with hepatitis B virus and/or hepatitis C virus is a risk factor for HIV virological rebound after achieving virological suppression on first ART: results from ICONA cohort <i>V Malagnino*; A Cozzi-Lepri; V Svicher; E Girardi; C Perno; A Saracino; G Cuomo; S Rusconi; M Puoti; A D'Arminio Monforte; M Andreoni; L Sarmati (Rome, Italy)</i>
P202 Virtual	Persistently high rates of HCV viraemia among high-risk people living with HIV in Taiwan in the era of direct-acting antivirals <i>H Sun*; L Su; Y Chen; S Huang; Y Huang; S Ho; W Liu; Y Su; S Chang; C Hung (Taipei, Taiwan)</i>
P203	Liver fibrosis and steatosis in hepatitis B-positive individuals with and without HIV coinfection in Senegal <i>A Ramírez Mena*; K Ndiaye; J Tine; A Gaye; L Fortes; O Ndiaye; D Ka; M Fall; N Ngom; M Seydi; G Wandeler (Bern, Switzerland)</i>
P204	Long-term trends in qHBsAg levels in persons with and without functional HBV cure in the Swiss HIV Cohort Study <i>L Bègré*; A Boyd; F Suter-Riniker; C Bèguelin; J Rockstroh; H Günthard; A Calmy; M Cavassini; M Stöckle; P Schmid; E Bernasconi; M Levrero; F Zoulim; G Wandeler; A Rauch (Bern, Switzerland)</i>
P205	HCV testing training for non-HCV specialists in a tertiary hospital: change in attitudes and rates of HCV screening <i>A García García*; M Vivancos Gallego; J Martínez Sanz; C Cano; A González-Sarria; B Romero; M Sánchez Conde; M Vélez Díaz-Pallarés; F Gea Rodríguez; J Galán Montemayor; M Pérez Elías (Madrid, Spain)</i>
P206	Hepatitis A outbreak in men who have sex with men in a tertiary care facility in Romania <i>C Oprea*; A Paun; T Paduraru; I Popa; I Ianache (Bucharest, Romania)</i>
P207	Liver transplantation due to fulminant HBV infection in individuals whose HIV infection was diagnosed during pretransplant evaluation: report on two cases <i>A Gutierrez Villanueva; A Arias Milla; P Ruiz; A Diaz de Santiago; A Forner; M Laguno; V Cuervas-Mons; L Benitez; A Moreno; A Moreno Maroto; A Rimola; J Miró* (Barcelona, Spain)</i>



Scientific Posters

Viral Hepatitis (continued)

P208	Detectable HBV viraemia in HIV/HBV co-infected patients undergoing HBV active antiretroviral therapy <i>G Morsica; R Lolatto; C Bertoni*; A Siribelli; M Bottanelli; H Hasson; A Castagna; C Uberti-Foppa; A Siribelli (Milan, Italy)</i>
-------------	---

Clinical Pharmacology

P209	Physiologically based pharmacokinetic modelling of long-acting rilpivirine in pregnancy <i>S Atoyebi*; S Granana-Castillo; M Siccardi; C Waitt (Liverpool, UK)</i>
P210	Effects of the HIV-1 maturation inhibitor GSK3640254 on QT interval in healthy participants <i>Y Zhang*; M Johnson; M Bush; P Yazdani; J Zhan; B Wen; V Bainbridge; B Wynne; S Joshi; M Lataillade (Durham, NC, USA)</i>
P211 Virtual	Bioequivalence of a paediatric fixed-dose combination tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide compared with coadministration of the separate agents in healthy adults <i>S Van Hemelryck*; E Van Landuyt; J Ariyawansa; S Vanveggel; M Palmer (Beerse, Belgium)</i>
P212 Virtual	Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults <i>S Van Hemelryck*; E Van Landuyt; J Ariyawansa; M Palmer; M Kothe; C Pollefliet (Beerse, Belgium)</i>

Models of Care: Evaluation of ARV Delivery and Coverage

P213	Use of generic antiretroviral drugs in 2021 in three health centres in the Paris area, France <i>P Leroy*; S Diamantis; P Sellier; G Hamet; A Brun; W Rozenbaum; J Molina (Paris, France)</i>
P215	Cascade of care in Romanian patients who grew up with HIV from a tertiary care facility <i>I Ianache; R Radoi; G Tardei; L Ene; C Oprea* (Bucharest, Romania)</i>
P216 Virtual	Pilot model of the HIV drug resistance testing coverage cascade <i>A Pokrovskaya*; D Kireev; K Emerole; A Kirichenko; V Pokrovsky (Moscow, Russian Federation)</i>
P217	Residual viraemia and viral blips in the modern cART era: a glimpse beneath the surface <i>P Oomen*; S Dijkstra; A Hoepelman; B van Welzen (Utrecht, Netherlands)</i>

Virology and Immunology: Biomarkers

P218	ACBP and control of HIV in progressors and elite controllers <i>S Isnard; L Royston; J Lin; B Fombuena; S Bu; S Kant; T Mabanga; C Berini; M Durand; M El-Far; C Tremblay; N Bernard; G Kroemer; J Routy* (Montreal, Canada)</i>
P219	The preservation of thymic activity and the naïve T cell compartment is a hallmark of HIV-2 and early treated HIV-1 individuals <i>G Farias; R Marques; D Santos; A Gomes; Z Junginger; A Sousa; R Badura* (Lisbon, Portugal)</i>
P220	Reactive oxygen species (ROS) in T-cell subsets of HIV+cART naïve and HIV+cART+ individuals <i>R Emilova*; Y Todorova; M Aleksova; I Alexiev; L Grigorova; R Dimitrova; N Yancheva; M Nikolova (Sofia, Bulgaria)</i>



Scientific Posters

Virology and Immunology: Resistance	
P221 Virtual	Development of second-generation integrase inhibitor resistance over the last 6 years in Germany <i>F Wiesmann; A Maennling; G Naeth; P Braun; H Knechten* (Aachen, Germany)</i>
P222	Long-term efficacy and resistance analyses of D/C/F/TAF in the phase III AMBER and EMERALD studies: post 96-week data <i>E Lathouwers*; B Baugh; S Vanveggel; E Van Landuyt; M Opsomer; C Orkin; J Eron (Beerse, Belgium)</i>
P223	Reverse transcriptase M184V resistance mutation: back to the future? <i>E Teyssou; C Soulie; R Palich; A Nouchi; B Abdi; C Katlama; M Wirden; V Pourcher; A Marcelin; V Calvez* (Paris, France)</i>
P224	Phenotypic analyses of clinical isolates with capsid substitutions observed in people with HIV (PWHIV) treated with lenacapavir <i>N Margot*; V Naik; M Hendricks; L VanderVeen; S Yant; C Callebaut (Foster City, CA, USA)</i>
P225	The Virostar study: analysis of emergent resistance-associated mutations at first- or second-line HIV-1 virological failure with second-generation INSTIs in two- and three-drug regimens <i>A Marcelin*; C Soulie; M Wirden; C Charpentier; D Descamps; V Calvez (Paris, France)</i>
P226	Integrase inhibitors mutational viral load in HIV-infected pregnant women in Argentina <i>D Cecchini*; J Sfalcin; I Zapiola; A Gomez; S Fernandez Giuliano; C Rodriguez; L Mammana; A Seravalle; F Fay; G Bugarín; M Bouzas (Buenos Aires, Argentina)</i>
Virology and Immunology: Other	
P227 Virtual	Effect of HIV-1 subtype C transactivator of transcription (Tat) P21A variant on nuclear levels of active positive transcription elongation factor b (P-TEFb), TAR binding and disease outcome <i>Z Mkhize*; D Boehm; R Crespo-Galvan; M Ott; T Mahmoudi; T Ndung'u; P Madlala (Durban, South Africa)</i>
P228	Initial plasma HIV-1 RNA and CD4+ T-cell count are determinants of virological outcomes with initial integrase inhibitor-based regimens: a prospective multinational RESPOND cohort consortium <i>H Álvarez*; A Mcroft; L Ryom; B Neesgaard; S Edwards; V Svedhem-Johansson; H Günthard; R Zangerle; C Smith; A Castagna; A d'Arminio Monforte; F Wit; M Stecher; C Lehman; C Mussini; E Fontas; E González; J-C Wasmuth; A Sönnnerborg; S De Wit; N Chkhartishvili; C Stephan; K Petoumenos; N Jaschinski; V Vannappagari; J Rooney; I Young; A volny-Anne; L Greenberg; R Martín-Iguacel; E Poveda; J Llibre; for the RESPOND Study Group (Ferrol, A Coruña, Spain)</i>
P229	COVID-19 pandemic and continuum of care in a cohort of people living with HIV: will we have a price to pay in the future? <i>B Bellocchi*; M Ceccarelli; R Bruno; L Todaro; A Bandiera; E Pistarà; C Giarratana; V Boscia; G Nunnari; B Cacopardo; B Celesia (Catania, Italy)</i>
P230 Virtual	Recent detectable viral loads among adults living with HIV in the Asia-Pacific between 2015 and 2020 <i>M Palatino*; D Rupasinghe; A Widhani; N Chi; I Somia; N Kumarasamy; S Khusuwan; V Khol; M Lee; S Kiertiburanakul; T Pham; S Pujari; A Avihingsanon; J Choi; R Chaiwarith; Y Chan; I Azwa; R Ditangco; R Borse; O Ng; J Tanuma; F Zhang; Y Gani; J Ross; A Jiamsakul (Columbia, SC, USA)</i>
P231	Contribution to the study of origin, evolution and pathogenesis of CRF19_cpx, a recombinant form of HIV-1 with high prevalence in Cuba <i>V Kouri*; L Pérez; Y Martínez; A Zhukova; A Suárez; O Gascuel; Y Pintos; L Machado; E Noa; M Dávila; J Voznica; T To; J Pérez (Havana, Cuba)</i>



Scientific Posters

Virology and Immunology: Other (continued)

P232	Viral reservoir diversity in circulating PMBC and T cell subsets under suppressive ART <i>Y Zhang*</i> ; <i>F Otte</i> ; <i>T Klimkait (Basel, Switzerland)</i>
P233 Virtual	Genetic characteristics of a novel HIV-1 recombinant lineage (CRF103_01B) and its prevalence in northern China <i>M Dai*</i> ; <i>J Li</i> ; <i>S Lv</i> ; <i>J Li</i> ; <i>H Lu</i> ; <i>H Huang</i> ; <i>R Xin (Shenyang, China)</i>
P234	HIV subtypes: where are we now? <i>C Afonso*</i> ; <i>A Zagalo</i> ; <i>A Ayres Pereira (Lisbon, Portugal)</i>
P235	FluVac: influenza vaccination in PLWHIV in Germany during flu seasons 2018/19 and 2019/20 - real-world data extraction from electronic health record systems used by general practitioners and specialists <i>E Wolf*</i> ; <i>A Balogh</i> ; <i>C Roll</i> ; <i>S Noe</i> ; <i>N Postel</i> ; <i>H Heiken</i> ; <i>I Ruck</i> ; <i>W Schmidt</i> ; <i>U Kutscher</i> ; <i>U Meyer-Bunsen</i> ; <i>S Preis (Munich, Germany)</i>

Late Presenters

P236	Estimating the risk of mortality attributable to late HIV diagnosis following admission to the intensive care unit: a single-centre observational cohort study <i>N Bakewell*</i> ; <i>T Kanitkar</i> ; <i>O Dissanayake</i> ; <i>M Symonds</i> ; <i>S Rimmer</i> ; <i>A Adlakha</i> ; <i>M Lipman</i> ; <i>S Bhagani</i> ; <i>B Agarwal</i> ; <i>R Miller</i> ; <i>C Sabin (London, UK)</i>
P237	Improving the HIV testing cascade: implementing HIV teams to support HIV indicator condition-guided testing in general practice in the Netherlands <i>C Jordans*</i> ; <i>D van Otterdijk</i> ; <i>L Rokx-Niemantsverdriet</i> ; <i>J Struik</i> ; <i>P van der Voorn</i> ; <i>E van der Waal</i> ; <i>N Bakker</i> ; <i>C Rokx (Rotterdam, Netherlands)</i>
P238	Late diagnosis of HIV during the COVID-19 pandemic in a LMIC: an emerging challenge <i>B Domecq</i> ; <i>X Varrese</i> ; <i>V Ortiz</i> ; <i>R Zhumi Chacón</i> ; <i>N D'Amico</i> ; <i>M Bertolini</i> ; <i>C Frola</i> ; <i>J Barletta</i> ; <i>M Jaume</i> ; <i>A Sisto</i> ; <i>M Rolón*</i> (Buenos Aires, Argentina)
P239 Virtual	Missed opportunities for an early HIV diagnosis in Greece (MORFEAS): preliminary results <i>S Roussos*</i> ; <i>K Protopapas</i> ; <i>A Antoniadou</i> ; <i>A Papadopoulos</i> ; <i>G Lourida</i> ; <i>V Papastamopoulos</i> ; <i>M Chini</i> ; <i>K Alexakis</i> ; <i>E Barbounakis</i> ; <i>D Kofteridis</i> ; <i>L Leonidou</i> ; <i>M Marangos</i> ; <i>V Petrakis</i> ; <i>P Panagopoulos</i> ; <i>E Mastrogrianni</i> ; <i>P Palla</i> ; <i>N Sipsas</i> ; <i>V Pappazotos</i> ; <i>S Metallidis</i> ; <i>I Katsarolis</i> ; <i>V Sypsa</i> ; <i>M Psychogiou (Athens, Greece)</i>
P240	Impact of the COVID-19 pandemic on the diagnosis of late presenters of HIV-infected patients at a tertiary hospital in Lisbon, Portugal in 2018 to 2021 <i>S Casanova</i> ; <i>J Borralho*</i> ; <i>C Fernandes</i> ; <i>A Miranda</i> ; <i>J Vasconcelos</i> ; <i>J Alves</i> ; <i>S Peres</i> ; <i>T Baptista</i> ; <i>I Antunes</i> ; <i>F Borges</i> ; <i>J Nina</i> ; <i>K Mansinho (Lisbon, Portugal)</i>
P241	Persisting and emerging challenges of late HIV presentation in Germany <i>C Boesecke</i> ; <i>S Schellberg*</i> ; <i>J Schneider</i> ; <i>G Schuettfort</i> ; <i>H Stocker (Berlin, Germany)</i>



Scientific Posters

COVID-19: In the Context of HIV

P242	<p>Humoral immunogenicity to third dose SARS-CoV-2 mRNA vaccine in people living with HIV (PLWHIV) by current CD4 count and CD4/CD8 ratio</p> <p><i>A Vergori*</i>; A Cozzi Lepri; A Tavelli; M Giannella; S Cicalini; L Marconi; V Yellenki; S Meschi; G Pellicanò; N Carocchia; G Matusali; A Latini; M Lichtner; S Lo Caputo; F Fusco; G Marchetti; E Tacconelli; A Antinori; A D'Arminio Monforte (Rome, Italy)</p>
P243	<p>Evolution of anti-SARS-CoV-2 spike protein titers after two-dose COVID-19 vaccination among people living with HIV</p> <p><i>W Liu*</i>; S Chang; J Wang; H Sun; Y Huang; K Lin; U Wu; G Li; W Liu; Y Su; P He; C Lin; C Yeh; Y Chen; Y Luo; P Wu; L Chen; H Chang; W Sheng; S Hsieh; C Hung; S Chang (Taipei City, Taiwan)</p>
P244	<p>COVID-19 in HIV-infected patients: does tenofovir-based ART have any impact?</p> <p><i>F Rombini; D Cecchini*</i>; D Pinto; L Calanni; R Cuini; E Obieta; M Greco; F Morales; C Migazzi; L Morganti; Y El Kozah; P Parenti; I Cassetti (Buenos Aires, Argentina)</p>
P245 Virtual	<p>Antibody response and HIV-1 RNA response following a booster of SARS-CoV-2 vaccination in people living with HIV</p> <p><i>C Fedeli*</i>; P Ustero; V Portillo; E Mereles; I Savkarelidze; M Puntel; I Petignat; C Jaksic; S Yerly; A Calmy (Geneva, Switzerland)</p>
P246	<p>Lower T-cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people living with HIV</p> <p><i>P Vizcarra; S Martín-Colmenarejo; J del Pino; M Perez-Elías; A Moreno*</i>; S Gomez-Maldonado; A Martín-Hondarza; A Abad; A Vallejo; J Casado (Madrid, Spain)</p>
P248	<p>T-cell and humoral responses to mRNA-1273 vaccine up to 6 months in late presenter (LP) people living with HIV (PLWH)</p> <p><i>M Augello*</i>; V Bono; R Rovito; V Yellenki; C Tincati; A d'Arminio Monforte; G Marchetti (Milan, Italy)</p>
P249	<p>An investigation into the psychological impact of the COVID-19 pandemic for people living with HIV</p> <p><i>S Lo*</i>; L Muschialli; T Fernandez; D Peppas; F Burns (London, UK)</p>
P250	<p>Immunogenicity of homologous versus heterologous prime-boost vaccination regimens against SARS-CoV-2 in people living with HIV in Argentina: a pilot study</p> <p><i>R Mauas*</i>; D Cecchini; A Urueña; M Strada; S Arietti; I Cassetti (Ciudad Autónoma de Buenos Aires, Argentina)</p>
P251	<p>Immunogenicity of AZD1222 (ChAdOx1) SARS-CoV-2 vaccine in people living with HIV</p> <p><i>J Begovac*</i>; S Zekan; N Cetinic Balent; I Javoric; N Bogdanic; R Mikulic; O Dakovic Rode (Zagreb, Croatia)</p>
P252	<p>Does COVID-19 vaccination have a striking protective effect in HIV infected people? A real-life experience of a Portuguese centre</p> <p><i>C Fernandes*</i>; A Duarte; J Alves; S Peres; A Miranda; T Baptista; I Antunes; F Borges; J Nina; K Mansinho (Leiria, Portugal)</p>
P253	<p>The impact of COVID-19 pandemic in HIV diagnosis: the experience of a Central Hospital in Lisbon, Portugal</p> <p><i>C Fernandes*</i>; S Casanova; J Borralho; A Miranda; J Alves; S Peres; T Baptista; I Antunes; F Borges; J Nina; K Mansinho (Leiria, Portugal)</p>



Scientific Posters

COVID-19: In the Context of HIV (continued)

P254	Humoral immune response of patients living with HIV (PLWHIV) after three doses of mRNA BNT162b2 SARS-CoV-2 vaccine: a prospective cohort study <i>L Tau*</i> ; <i>T Halperin</i> ; <i>A Adler</i> ; <i>R Marom</i> ; <i>S Ahsanov</i> ; <i>N Matus</i> ; <i>I Levy</i> ; <i>G Gerber</i> ; <i>S Lev</i> ; <i>T Ziv-Baran</i> ; <i>D Turner</i> (Tel-Aviv, Israel)
P255	The vaccinations against COVID-19 efficacy and safety among people living with HIV: data from observational study in Poland <i>A Skrzat-Klapaczynska</i> ; <i>C Bienkowski</i> ; <i>J Kowalska*</i> (Warsaw, Poland)
P256	The impact of the pandemic on PLWHIV: issues and opportunities for rethinking PLWHIV care management <i>G Marchetti*</i> ; <i>S Lo Caputo</i> ; <i>S Mattioli</i> ; <i>M Sacchi</i> ; <i>L Brogonzoli</i> ; <i>R Iardino</i> (Milano, Italy)
P257	Did COVID-19 impact HIV control? Time to undetectable HIV viral load in newly HIV-1 diagnosed patients before and during pandemic <i>J Borralho*</i> ; <i>S Casanova</i> ; <i>C Fernandes</i> ; <i>J Vasconcelos</i> ; <i>J Alves</i> ; <i>S Peres</i> ; <i>A Miranda</i> ; <i>T Baptista</i> ; <i>I Antunes</i> ; <i>F Borges</i> ; <i>J Nina</i> ; <i>K Mansinho</i> (Lisboa, Portugal)

COVID-19: Novel Therapeutics

P258	Retrospective study comparing outcome, safety and virological clearance at day 7 in patients with mild-moderate COVID-19 disease treated with molnupiravir, nirmatrelvir/ritonavir and short-course of remdesivir <i>T Beringheli*</i> ; <i>F Bai</i> ; <i>V Vitaletti</i> ; <i>F Molà</i> ; <i>A Copes</i> ; <i>N Gemignani</i> ; <i>S Pettenuzzo</i> ; <i>D Barbanotti</i> ; <i>G Mulè</i> ; <i>R Castoldi</i> ; <i>B Varisco</i> ; <i>R Nardo</i> ; <i>L Lundgren</i> ; <i>L Albertini</i> ; <i>M Augello</i> ; <i>L Biasioli</i> ; <i>C Falcinella</i> ; <i>D Tomasoni</i> ; <i>G Marchetti</i> ; <i>A d'Arminio Monforte</i> (Milan, Italy)
P259	Vaccination and anti-SARS-CoV-2 treatment reduce disease progression: a real-life experience <i>A De Vito*</i> ; <i>A Colpani</i> ; <i>L Saderi</i> ; <i>B Zauli</i> ; <i>A Bitti</i> ; <i>M Fois</i> ; <i>C Di Castri</i> ; <i>M Meloni</i> ; <i>M Puci</i> ; <i>S Bacciu</i> ; <i>V Fiore</i> ; <i>I Maida</i> ; <i>S Babudieri</i> ; <i>G Sotgiu</i> ; <i>G Madeddu</i> (Sassari, Italy)
P260	MP3 pulses COVID 19 trial: effect of intravenous pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalised adults with severe COVID-19 pneumonia <i>J Abadía Otero*</i> ; <i>L Corral Gudino</i> ; <i>I Cusacovich</i> ; <i>J Martín González</i> ; <i>A Muela Molinero</i> ; <i>R González Fuentes</i> ; <i>Á Ruiz de Temiño</i> ; <i>E Tapia Moral</i> ; <i>F Cuadrado Medina</i> ; <i>M Martín Asenjo</i> ; <i>P Miramontes González</i> (Valladolid, Spain)

Monkeypox Virus

P261	Clinical description of 50 cases of monkeypox virus (MKPV) infection among MSM in an HIV/PrEP French clinic <i>E Rubenstein*</i> ; <i>M Sarda</i> ; <i>C Lascoux</i> ; <i>C Pintado</i> ; <i>J Zeggagh</i> ; <i>D Ponscarne</i> ; <i>M Tateo</i> ; <i>S Chawki</i> ; <i>G Liegeon</i> ; <i>J Gras</i> ; <i>M Lafaurie</i> ; <i>N De Castro</i> ; <i>D Descamps</i> ; <i>J Molina</i> (Paris, France)
P262	First monkeypox cases in patients living with HIV from Romania <i>C Oprea*</i> ; <i>I Ianache</i> ; <i>S Piscu</i> ; <i>A Paun</i> ; <i>D Topa</i> ; <i>G Tardej</i> ; <i>C Popescu</i> ; <i>S Florescu</i> (Bucharest, Romania)